Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 21, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for June 5, 2004 Subscribe to this News Feed      
 

First OTC Product for IBS Sufferers in Major Drug Retail Chains Now.

STOMACH IN SOMERSAULTS? IBS IS THE CULPRIT FOR MILLIONS. New Product Helps Sufferers Fight the Battle Irritable bowel syndrome (IBS), once relatively unknown, is a disorder that has become increasingly more pervasive in todays society.

(PRWEB) June 5, 2004 --Irritable bowel syndrome (IBS), once relatively unknown, is a disorder that has become increasingly more pervasive in todays society. In fact, it is estimated 1 out of 5 people are currently diagnosed with the disorder, 75 percent of whom are women. IBS is characterized by abdominal pain or discomfort, and altered bowel habit (chronic or recurrent diarrhea, constipation or both in fluctuation). The condition is truly life altering for some and the distressing symptoms include bloating, cramping, gas, mucus in stool, urgency, diarrhea and/or constipation. It can be quite uncomfortable and has been characteristically difficult to treat because the disorder manifests itself by presenting the sufferer with alternating symptoms. IBS is exacerbated by stress and menstruation, leaving women who are afflicted with the disease suffering relentlessly.

Over 55% of IBS sufferers need daily relief and 67% of those with IBS are not satisfied with current medications. Until recently, the only over the counter options available to treat this condition has been Immodium for diarrhea or Metamucil for constipation. To fulfill the increasing need among patients and doctors for a viable treatment, the pharmaceutical industry then responded with two drugs, Zelnorm and Lotronex. These drugs have been met with controversy because they have actually resulted in patient deaths. This has left patients seeking treatment with nowhere to turn for relief, until now.

Digestive Advantage IBS is a medical food for the dietary management of Irritable Bowel Syndrome, safely and effectively. It is formulated to manage the full range of irritable bowel syndrome symptoms. The power behind Digestive Advantage IBS is a patented blend of lactobacillus cultures with an amino acid that normalizes the flora the gut and aids digestion of dairy, fruits, meats, and carbohydrates. Digestive Advantage IBS is the first of its kind because it helps to relieve both ends of the IBS spectrum: Diarrhea and Constipation. The product has provided patients with a real solution to the condition and 92% of those who are using the product have responded miraculously.

Digestive Advantage IBS is a chewable tablet taken once per day and provides 24-hour relief. The product is available at 9 of the 10 largest drug store chains in the US including Walgreens, Rite-Aid, CVS and Eckerd and on line at Drugstore.com, CVS.com and numerous other drug and food chains with a price point of $10.99.

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Katherine Rothman
KMR COMMUNICATIONS, INC
212 213-6444
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright